One of the challenges haematologists face in myeloma is how to treat frailer patients. Whilst the availability of proteasome inhibitors (PIs) (e.g. bortezomib [Velcade®], ixazomib [Ninlaro®] and carfilzomib [Kyprolis®]) and immunomodulatory agents (IMiDs) (e.g. thalidomide, lenalidomide [Revlimid®] and pomalidomide [Imnovid®]), have significantly improved the outcomes of myeloma patients in the last decade, frailer patients have shown a lesser improvement. This is mainly due to the toxicity some drugs can have in frailer patients, which may lead to subsequent early discontinuation of treatment. Continue reading
It is with great sadness that we inform you that our friend and colleague Wiesława Adamiec, President of Fundacja Carita (Poland), has passed away. Continue reading
A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America, according to the announcement the European Society of Medical Oncology (ESMO) has done today. Continue reading
The contribution of patients and patient experts provides tangible value to other stakeholders and society that should be fairly compensated. Currently, there is no transparent and consistent system for financial compensation in place that reflects the level of individual contribution and expertise. Continue reading
Daratumumab (Darzalex®), an immunotherapy drug for the treatment of myeloma, has received a positive recommendation by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Continue reading
At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020 CARAMBA project.
MPE is collaborating with a consortium of European partners, including the University of Würzburg, on CARAMBA which is studying an innovative new treatment called chimeric antigen receptor T-cell (CAR-T) therapy in myeloma. In this video, Michael explains CAR-T cell therapy and the Horizon2020 CARAMBA project in more detail. Continue reading
The most important scientific meeting about haematological diseases in Europe, the European Haematology Association (EHA) Annual Meeting, took place in Stockholm from 14 to 17 June 2018. Immunotherapy, CAR-T cell therapy and drug combinations were some of the key topics presented. Continue reading
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the European Hematology Association (EHA) that took place in Stockholm, Sweden in June 2018.
The talk will be given by Dr Laurent Garderet, Department of Hematology, Saint Antoine Hospital, Paris, France. Continue reading
Myeloma Patients Europe (MPE) recently held the first face-to-face meeting of the Advocate Development Programme (ADP) in Stockholm, Sweden during the European Haematology Association (EHA) Annual Congress 2018. Continue reading
The Myeloma Patients Europe (MPE) team has been busy attending several important international conferences focusing on myeloma and AL amyloidosis.
Main conferences attended were the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 and the European Haematology Association (EHA) Annual Congress 2018. These large-scale meetings bring together oncology and haematology professionals from across the globe to discuss the latest scientific and treatment developments in the field. The scientific and patient advocacy highlights are outlined below.